DIA study links more oversight to better orphan drug access

07/30/2013 | PharmExec.com

A study sponsored by DIA found that countries with more regulatory structures for advancing treatments for rare diseases have greater access by patients to orphan drugs compared with countries with less extensive regulatory frameworks. The U.S. did not do as well as France, Spain, the U.K. and Germany in providing access to 13 orphan treatments, according to the study.

View Full Article in:

PharmExec.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY